| Dr Aaron C Macdonald, MD | |
|
109 Montgomery Dr, Anderson, SC 29621-3333 | |
| (864) 512-7190 | |
| (864) 226-0680 |
| Full Name | Dr Aaron C Macdonald |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 33 Years |
| Location | 109 Montgomery Dr, Anderson, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649282245 | NPI | - | NPPES |
| 192990 | Medicaid | SC | |
| 19299 | Other | SC | SC LICENSE NUMBER |
| P01616447 | Other | SC | RR MEDICARE |
| 00777532A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 19299 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anmed Health | Anderson, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anmed Health | 1951215243 | 276 |
News Archive
A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.
Oxford Gene Technology, The Molecular Genetics Company, has released a new application note detailing the technical evaluation of two DNA labelling kits, where OGT's CytoSure Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.
Men whose mothers, sisters or daughters test positive for a cancer-causing gene mutation also have an increased risk of developing the disease but are unaware of that risk.
Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects.
› Verified 1 days ago
| Entity Name | Anmed Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639102270 PECOS PAC ID: 1951215243 Enrollment ID: O20040130000302 |
News Archive
A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.
Oxford Gene Technology, The Molecular Genetics Company, has released a new application note detailing the technical evaluation of two DNA labelling kits, where OGT's CytoSure Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.
Men whose mothers, sisters or daughters test positive for a cancer-causing gene mutation also have an increased risk of developing the disease but are unaware of that risk.
Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aaron C Macdonald, MD Po Box 100174, Columbia, SC 29202-3174 Ph: (864) 512-7190 | Dr Aaron C Macdonald, MD 109 Montgomery Dr, Anderson, SC 29621-3333 Ph: (864) 512-7190 |
News Archive
A new SARS-CoV-2 vaccine candidate, developed by giving a key protein's gene a ride into the body while encased in a measles vaccine, has been shown to produce a strong immune response and prevent SARS-CoV-2 infection and lung disease in multiple animal studies.
Oxford Gene Technology, The Molecular Genetics Company, has released a new application note detailing the technical evaluation of two DNA labelling kits, where OGT's CytoSure Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.
Men whose mothers, sisters or daughters test positive for a cancer-causing gene mutation also have an increased risk of developing the disease but are unaware of that risk.
Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects.
› Verified 1 days ago
Dr. Larry Steve Davidson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 109 Montgomery Dr, Anderson, SC 29621 Phone: 864-224-5700 Fax: 864-226-0680 |